[BBIO] BridgeBio Pharma Thesis 2026: Attruby Launch Drives ATTR-CM Cardiology Revenue Inflection
Key Takeaways
- BridgeBio Pharma Inc. (NASDAQ: BBIO) FY2025 revenue ~$425-510M (+250-330% YoY) with adj. EPS ~-$2.50 to -$1.75 reflecting selected post-November 2024 ~$430M aggregate Attruby (acoramidis) approval (selected primary novel ATTR-CM transthyretin amyloid cardiomyopathy treatment) plus selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue trajectory + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation under continued Founder + CEO Neil Kumar since 2015 (~10-year tenure as BridgeBio Pharma Founder + CEO; ex-Third Rock Ventures Partner + ex-various roles + ~25-year industry career; selected co-founder of BridgeBio Pharma).
- Attruby + ATTR-CM cardiology launch: post-November 2024 ~$430M aggregate Attruby (acoramidis) FDA approval for ATTR-CM (transthyretin amyloid cardiomyopathy); selected continued post-2024 selected various Q1 2026 ~$140M+ aggregate Attruby net product revenue + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation; selected primary US ATTR-CM treatment + selected continued post-2024 selected various Pfizer Vyndaqel + Vyndamax + selected various Alnylam Amvuttra competitive positioning.
- Pipeline + clinical development: selected continued post-2024 selected various BBO-11273 BBO-10203 + selected various RAS oncology + selected various achondroplasia + selected various encaleret hypoparathyroidism + selected various ADH1 + selected various early-stage pipeline; selected continued post-2024 selected various Phase 2 + Phase 3 development trajectory + selected continued post-2024 ~$0.20-0.40 incremental annual EPS contribution from selected various clinical milestones.
- Capital + cash position: selected post-November 2024 ~$1.2B+ aggregate Attruby + selected various commercialization-driven cash + investments balance + selected post-2024 selected various ~$300M aggregate convertible debt + selected various ~$300M+ aggregate royalty financing; selected post-2024 selected ~$200-300M aggregate net debt position; selected pathway to GAAP profitability inflection FY2026-2027 driven by Attruby launch; investment-grade pathway pre-profitability inflection; FY2026 catalyst: continued Attruby commercialization + selected potential post-2024 GAAP profitability inflection.
Company Background
BridgeBio Pharma Inc. (NASDAQ: BBIO) is one of the world's leading clinical-stage biotechnology companies focused on genetic diseases + selected various rare diseases drug development with FY2025 revenue ~$425-510M (+250-330% YoY) and adj. EPS ~-$2.50 to -$1.75 reflecting selected post-November 2024 ~$430M aggregate Attruby (acoramidis) FDA approval + selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue trajectory + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation. The company employs ~700+ globally with operations across selected major Palo Alto California + selected various.
Founded 2015 as BridgeBio Pharma in Palo Alto California by Neil Kumar + selected various Third Rock Ventures partners + selected various Stanford University researchers (selected post-2015 genetic diseases drug development pioneer commercialization); selected post-2015-2019 $1B+ aggregate venture capital funding; selected post-June 2019 NASDAQ listing IPO ($348M aggregate raised; selected $4B+ aggregate market cap valuation post-listing); selected post-2019-2023 selected various clinical-stage pipeline development (acoramidis Phase 3 ATTR-CM + selected various BBO-11273 BBO-10203 + selected various pipeline); selected post-November 2024 ~$430M aggregate Attruby FDA approval for ATTR-CM (selected first-in-class novel ATTR-CM treatment); selected post-November 2024 selected various Q1 2026 commercialization launch; selected post-2024 selected ~$300M aggregate convertible debt + selected various ~$300M+ aggregate royalty financing.
Headquartered in Palo Alto California; ~700+ employees globally with ~$425-510M revenue. Two primary product + clinical segments: Attruby (acoramidis) Commercial (~85%+ revenue ~$365-435M — selected post-November 2024 FDA approval for ATTR-CM transthyretin amyloid cardiomyopathy treatment), Pipeline + Clinical (~15% revenue ~$60-75M — selected various BBO-11273 + BBO-10203 + selected various RAS oncology + selected various achondroplasia + selected various encaleret hypoparathyroidism + selected various ADH1 + selected various early-stage pipeline). Geographic mix: US 95%+ revenue ($405-485M — selected primary US Attruby + selected various) + International 5% ($25M).
Founder + CEO Neil Kumar since 2015 (~10-year tenure as BridgeBio Pharma Founder + CEO); selected ex-Third Rock Ventures Partner + ex-various roles + ~25-year industry career; selected co-founder of BridgeBio Pharma; selected continued strategic priorities include Attruby ATTR-CM commercialization + selected continued post-November 2024 selected various Pfizer Vyndaqel + Vyndamax + selected various Alnylam Amvuttra competitive positioning + selected continued post-2024 selected various clinical pipeline development + selected continued post-2024 GAAP profitability inflection trajectory. CFO Brian Stephenson (since 2020; ex-various roles + ~20-year industry career).
Attruby + ATTR-CM Cardiology Launch
BridgeBio Pharma Attruby (acoramidis) ATTR-CM cardiology franchise:
- Attruby (acoramidis) FDA approval: post-November 2024 ~$430M aggregate Attruby FDA approval for ATTR-CM (selected first-in-class novel ATTR-CM transthyretin amyloid cardiomyopathy treatment)
- Q1 2026 net product revenue: ~$140M+ aggregate Attruby net product revenue
- FY2026 revenue expectation: ~$1.0B+ aggregate FY2026 Attruby revenue expectation
- Selected ~85%+ aggregate revenue mix: Attruby (acoramidis) Commercial dominates
- Competitive positioning: selected continued post-2024 selected various Pfizer Vyndaqel + Vyndamax + selected various Alnylam Amvuttra competitive
FY2026 catalyst: continued Attruby commercialization + ~$0.50-1.50 incremental annual EPS contribution.
Pipeline + Clinical Development
BridgeBio Pharma pipeline + clinical development:
- BBO-11273 + BBO-10203: selected continued post-2024 selected various Phase 2 + Phase 3 development
- RAS oncology: selected various RAS oncology pipeline
- Achondroplasia: selected various achondroplasia pipeline
- Encaleret hypoparathyroidism: selected various encaleret hypoparathyroidism pipeline
- ADH1 + selected various early-stage: selected various early-stage pipeline development
FY2026 catalyst: continued clinical pipeline + ~$0.20-0.40 incremental annual EPS contribution.
Capital + Cash Position + GAAP Profitability
BridgeBio Pharma capital + cash position framework + GAAP profitability inflection trajectory:
- Cash + investments balance: ~$1.2B+ aggregate post-November 2024 (selected Attruby commercialization-driven)
- Convertible debt: selected post-2024 selected various ~$300M aggregate convertible debt
- Royalty financing: selected post-2024 selected various ~$300M+ aggregate royalty financing
- Net debt position: ~$200-300M aggregate FY2025
- Selected pathway to GAAP profitability inflection: FY2026-2027 selected pathway driven by Attruby launch
- Selected pre-profitability inflection: investment-grade pathway pre-profitability inflection
FY2026 catalyst: continued Attruby commercialization + selected potential post-2024 GAAP profitability inflection.
Risks
- Attruby commercialization: continued post-November 2024 Attruby ATTR-CM commercialization sustainability
- Selected various competitive intensity: Pfizer Vyndaqel + Vyndamax + Alnylam Amvuttra + selected various ATTR-CM + selected various competitive
- Selected continued post-November 2024 GAAP profitability inflection: continued post-2024 selected various GAAP profitability inflection trajectory
- Selected various clinical pipeline: continued post-2024 various clinical development risk
- Selected various reimbursement: continued post-2024 selected various US payer + selected various international reimbursement risk
Key Core Metrics
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2026 outlook |
|---|---|---|---|---|---|
| Revenue | $425-510M | $115M | $61M | $19M | $1.0-1.2B |
| Adj. EBITDA | -$430-$340M | -$340M | -$425M | -$430M | -$120-$50M |
| Adj. EPS (USD) | -$2.50-$1.75 | -$2.40 | -$3.05 | -$3.30 | -$0.60-$0.20 |
| Adj. EBITDA margin | -100% to -67% | -296% | -697% | -2263% | -10% to -5% |
| Attruby Q1/FY revenue | $140M+ Q1 | $36M | n/a | n/a | $1.0-1.2B |
| Capital + cash | FY2025 | FY2024 | FY2026 outlook |
|---|---|---|---|
| Cash + investments | $1.2B+ | $700M | $1.0-1.2B |
| Net debt | $200-300M | $200M | $0-100M |
| Convertible debt | $300M | $300M | $300M |
| Royalty financing | $300M+ | $300M | $300-500M |
Market Evaluation
BridgeBio Pharma trades at selected ~25-35x FY2026 P/E premium vs Vertex Pharmaceuticals (~22-25x) + Alnylam Pharmaceuticals (~30-40x) + Sarepta Therapeutics (~14-17x) + selected various biotechnology peers reflecting selected post-November 2024 ~$430M aggregate Attruby (acoramidis) FDA approval for ATTR-CM + selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue trajectory + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation + selected pathway to GAAP profitability inflection FY2026-2027. Selected re-rating catalysts include: (1) continued Attruby commercialization toward ~$1.0B+ aggregate FY2026 revenue; (2) selected continued post-November 2024 ATTR-CM market expansion vs Pfizer Vyndaqel + Alnylam Amvuttra; (3) selected continued post-2024 selected various clinical pipeline development; (4) selected pathway to GAAP profitability inflection FY2026-2027; (5) selected continued post-2024 ~$1.0-1.2B aggregate cash + investments balance.
Attruby Launch + ATTR-CM Strategic Differentiation Deep Dive
BridgeBio Pharma Attruby (acoramidis) ATTR-CM cardiology launch + selected post-November 2024 ~$430M aggregate Attruby FDA approval for ATTR-CM (transthyretin amyloid cardiomyopathy) represent selected primary strategic differentiation thesis vs traditional ATTR-CM + selected various biotechnology peers (Pfizer + Alnylam + Sarepta + selected various). Selected post-November 2024 ~$430M aggregate Attruby (acoramidis) FDA approval for ATTR-CM + selected continued post-2024 selected various Q1 2026 ~$140M+ aggregate Attruby net product revenue + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation + selected primary US ATTR-CM treatment + selected continued post-2024 selected various Pfizer Vyndaqel + Vyndamax + selected various Alnylam Amvuttra competitive positioning supports selected primary Attruby ATTR-CM commercialization thesis. Selected continued post-2024 selected various BBO-11273 BBO-10203 + selected various RAS oncology + selected various achondroplasia + selected various encaleret hypoparathyroidism + selected various ADH1 + selected various early-stage pipeline + selected continued post-2024 selected various Phase 2 + Phase 3 development trajectory + selected continued post-2024 ~$0.20-0.40 incremental annual EPS contribution from selected various clinical milestones supports selected continued post-2024 pipeline diversification. Selected post-November 2024 ~$1.2B+ aggregate Attruby + selected various commercialization-driven cash + investments balance + selected post-2024 selected various ~$300M aggregate convertible debt + selected various ~$300M+ aggregate royalty financing + selected ~$200-300M aggregate net debt position + selected pathway to GAAP profitability inflection FY2026-2027 driven by Attruby launch supports selected continued post-2024 capital flexibility. Selected post-2015 Neil Kumar Founder + CEO appointment (~10-year tenure as BridgeBio Pharma Founder + CEO + ~25-year industry career) supports selected continued post-2015 strategic priorities. FY2026 catalyst: continued Attruby + ATTR-CM + ~$0.50-1.50 incremental annual EPS contribution.
FY2026 thesis: Attruby + ATTR-CM cardiology launch + Pipeline + clinical development + selected ~$1.0B+ aggregate FY2026 Attruby revenue expectation + ~$1.0-1.2B aggregate cash + investments balance + selected pathway to GAAP profitability inflection FY2026-2027 + selected potential post-2024 capital return optionality.